Zosano Pharma is a commercially focused biopharmaceutical company enabling the systemic administration of therapeutics and other bioactive molecules to patients using our proprietary intracutaneous microneedle patch system. We have pioneered a novel paradigm for delivering molecules typically administered parenterally, where the inconvenience and pain associated with subcutaneous, intravenous or other complex administrations present barriers to compliance. Our strengths lie in our diverse team of industry veterans with proven drug and device development and significant commercialization experience.
Our lead clinical asset, Qtrypta*™ (zolmitriptan intracutaneous microneedle system), for the acute treatment of migraine with or without aura in adult patients, is currently under review by FDA. We expect that Qtrypta will be available, if approved, in 2021.
Rapid Acting
With our proprietary intracutaneous microneedle patch system, therapeutic blood levels are obtained more rapidly than with oral administration.
SIMPLE
Ready. Set. Apply. Three easy steps for administration.
*Qtrypta (zolmitriptan intracutaneous microneedle system) is the proposed commercial tradename.